TABLE 1.

Incidence of CMV disease in SOT patients in clinical trials with current preventative strategies

Type of transplant (references)	D+ R−			R+
	Incidence range among studies (%)	Weighted avg incidence (%) (no. of patients with CMV disease/total no. of patients)	Follow-up period	Incidence range among studies (%)	Weighted avg incidence (%) (no. of patients with CMV disease/total no. of patients)	Follow-up period
Kidney (23, 137, 269–273)	0–50	25 (183/739)	24 wks–1,236 daysa	2–15	7 (42/603)	3 mos–3 yrs
Liver (106, 150)	8–40	13 (13/258)	6–12 mos	0–4	3 (1/39)	12 mos
Lung (274, 275)	10–33	15 (4/26)	3–3.9b yr	7–19c	17 (25/150)	3–3.9b yrs
Heart (86, 276, 277)	0–25	10 (2/20)	6 mos	0–14	6 (7/127)	6–12 mos

^aMedian.

^bMean.

^cIncludes CMV disease events/patients.